Literature DB >> 17301071

Change in CA 125 levels after the first cycle of induction chemotherapy is an independent predictor of epithelial ovarian tumour outcome.

J M Riedinger1, F Bonnetain, J P Basuyau, N Eche, H Larbre, I Dalifard, J Wafflart, G Ricolleau, M F Pichon.   

Abstract

BACKGROUND: CA 125 assays enable treatment response monitoring in ovarian cancer. PATIENTS AND METHODS: This multicentric study was carried out to assess the prognostic value of the CA 125 change after the first and the second courses of induction chemotherapy (CT). Of the 494 stage IIc-IV patients, 194 had a surgical second look, 397 (80.4%) relapsed and 382 (77.3%) died from cancer. Median (range) follow-up time was 34 months (3-215 months).
RESULTS: In Cox models, CA 125 change after the first course (P < 0.0001), residual tumour (P = 0.003), CA 125 before the second course (P = 0.025) and patients' age (P = 0.048) were independent prognostic factors for overall survival (OS). A normal CA 125 before each of the two first CT courses or a CA 125 decrease >50% after the first course with a normal CA 125 before the second course identify patients with good prognosis. Both criteria retained a significant value in predicting second-look findings by univariate and multivariate analysis (P < 0.0001).
CONCLUSION: Among well-established prognostic factors in ovarian cancers, the CA 125 change after first course of CT was independent prognostic factors for both achievement of pathological complete response and OS.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17301071     DOI: 10.1093/annonc/mdl500

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  14 in total

1.  Progranulin is a potential prognostic biomarker in advanced epithelial ovarian cancers.

Authors:  Jasmine J Han; Minshu Yu; Nicole Houston; Seth M Steinberg; Elise C Kohn
Journal:  Gynecol Oncol       Date:  2010-10-15       Impact factor: 5.482

2.  Assessment of CA-125 area under the curve as a prognostic factor in patients with ovarian cancer.

Authors:  Sernaz Uzunoglu; Aysun Aybatlı; Petek Balkanlı Kaplan; Irfan Cicin; Necdet Sut; Cenk Sayın; Fusun Varol
Journal:  Med Oncol       Date:  2013-01-16       Impact factor: 3.064

3.  Longitudinal monitoring of CA125 levels provides additional information about survival in ovarian cancer.

Authors:  Digant Gupta; Carolyn A Lammersfeld; Pankaj G Vashi; Donald P Braun
Journal:  J Ovarian Res       Date:  2010-10-12       Impact factor: 4.234

4.  Effects of personal characteristics on serum CA125, mesothelin, and HE4 levels in healthy postmenopausal women at high-risk for ovarian cancer.

Authors:  Kimberly A Lowe; Chirag Shah; Erin Wallace; Garnet Anderson; Pamela Paley; Martin McIntosh; M Robyn Andersen; Nathalie Scholler; Lindsay Bergan; Jason Thorpe; Nicole Urban; Charles W Drescher
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-09       Impact factor: 4.254

Review 5.  Ovarian cancer biomarkers: current options and future promise.

Authors:  Christine M Coticchia; Jiang Yang; Marsha A Moses
Journal:  J Natl Compr Canc Netw       Date:  2008-09       Impact factor: 11.908

Review 6.  CA125-related tumor cell kinetics variables after chemotherapy in advanced ovarian cancer: a systematic review.

Authors:  G Colloca; A Venturino; I Governato
Journal:  Clin Transl Oncol       Date:  2015-11-06       Impact factor: 3.405

7.  A longitudinal analysis with CA-125 to predict overall survival in patients with ovarian cancer.

Authors:  An Jen Chiang; Jiabin Chen; Yu-Che Chung; Huan-Jung Huang; Wen Shiung Liou; Chung Chang
Journal:  J Gynecol Oncol       Date:  2014-01-08       Impact factor: 4.401

8.  Role of CA125 in predicting ovarian cancer survival - a review of the epidemiological literature.

Authors:  Digant Gupta; Christopher G Lis
Journal:  J Ovarian Res       Date:  2009-10-09       Impact factor: 4.234

9.  Ovarian cancer biomarkers: a focus on genomic and proteomic findings.

Authors:  Andrea Tinelli; Daniele Vergara; Roberta Martignago; Giuseppe Leo; Antonio Malvasi; Raffaele Tinelli; Santo Marsigliante; Michele Maffia; Vito Lorusso
Journal:  Curr Genomics       Date:  2007-08       Impact factor: 2.236

10.  An outlook on ovarian cancer and borderline ovarian tumors: focus on genomic and proteomic findings.

Authors:  Andrea Tinelli; Daniele Vergara; Roberta Martignago; Giuseppe Leo; Maurizio Pisanò; Antonio Malvasi
Journal:  Curr Genomics       Date:  2009-06       Impact factor: 2.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.